Companies

Biocon, Mylan get USFDA nod for pegfilgrastim drug substance licence

PTI New Delhi | Updated on November 27, 2019 Published on November 27, 2019

File photo

Biotechnology major Biocon on Wednesday said that US health regulator has approved its and Mylan’s supplemental biologics licence application for a drug substance to be manufactured at its new facility in Bengaluru.

“Biocon and Mylan’s supplemental biologics licence application (sBLA) for pegfilgrastim drug substance to be manufactured in Biocon’s new Biologics manufacturing facility has been approved by the US Food and Drug Administration (USFDA),” the company said in a filing to BSE.

This additional approval of its new manufacturing facility for pegfilgrastim in Bengaluru will enable the biotechnology major to enable its arm Biocon Biologics and Mylan to scale up capacity multi-fold and address the growing market opportunities in US and other global markets, the company said.

Biocon Biologics CEO Christiane Hamacher said, “This approval will help us better meet global patient needs for Fulphila, a high quality biosimilar pegfilgrastim co developed with Mylan and manufactured by Biocon Biologics“.

Biocon Biologics, through its partner Mylan, has commercialised three of its co-developed biosimilars in developed markets like the US, Canada, the European Union and Australia.

The USFDA had conducted pre-approval inspection of this new drug substance manufacturing facility from September 10-19, 2019. Shares of the company were trading at ₹277.45 apiece in morning trade on BSE.

Published on November 27, 2019
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.